ASHBURN, Va., March 16, 2026 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, has posted its 2025 fourth quarter and full year financial results on its investor relations website at https://investors.telos.com. Telos will host a live webcast to discuss its fourth quarter and full year 2025 financial results today, March 16, 2026, at 9:30 a.m. ET. To access the webcast, visit https://edge.media-server.com/mmc/p/p99edfa3/. Related presentation materials will be available in the Investors section of the Company’s website. In addition, an archived webcast will be posted on the website approximately two hours after the live event concludes. About Telos Corporation Telos Corporation (NASDAQ: TLS) empowers and...

CMD Generated $40.5 Million in Preliminary Unaudited 2025 Revenue, Representing 32% Year-Over-Year Growth Compared with CMD’s Full-Year 2024 Pro Forma Revenue, Which Reflects the Full Year of CMD Operations for Comparability CMD’s Preliminary Unaudited 2025 Net Income was $6.9 Million, Compared to Pro Forma Net Income of $7.5 Million in the Prior Year, a 7% Year-Over-Year Decrease. Adjusted EBITDA Increased to $14.3 Million from $7.7 Million in the Prior Year on a Pro Forma Basis, a 84% Year-Over-Year Increase CMD Management Noted a Record Bid Pipeline Exceeding $160 Million Kyle’s Generated $6.6 Million in Preliminary Unaudited 2025 Revenue, Up 24% from $5.3 Million in 2024. Net Loss Increased to $1.3 Million from $1.0 Million in the Prior Year, While Adjusted EBITDA More Than Doubled $1.1 Million from $0.6 Million Preliminary Consolidated...

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical development Capital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trialDOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the fourth quarter and full year ended December...

— Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million — — Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period — — Organizational Initiatives Drive Further Improvement in Margins — Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced strong results for the fourth quarter and transition period ended December 31, 2025. CEO Commentary “2025 was a highly productive year for Lifecore Biomedical, during which we strengthened our pipeline, leadership,...

Q3 Fiscal 2026 Highlights (compared to Q3 Fiscal year 2025)Record net income of $1.4 million versus net loss of $(1.0) million in Q3 FY2025 Operating expenses reduced 18% year-over-year, driving operating income of $1.7 million and 17% operating margin Adjusted EBITDA of $3.0 million (29% margin), up from $1.7 million (15% margin) in the prior-year quarter 2 Fifth consecutive quarter of positive operating cash flow, reaching $1.0 millionPHOENIX, March 16, 2026 (GLOBE NEWSWIRE) — Aspen Group, Inc. (OTCQB: ASPU) (“AGI” or the “Company”), an education technology holding company, today announced financial results for its third quarter of fiscal year 2026 ended January 31, 2026. Third Quarter Fiscal Year 2026 Summary Results  Three Months Ended January 31,   Nine Months Ended January 31,$ in millions, except per share data...

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiation of a pivotal Phase 3 clinical trial in early AD. The year was largely dedicated to the activation of clinical sites and the enrollment of participants across the United States. The Company also reported encouraging data from both its previous Alzheimer’s and Parkinson’s programs, demonstrating a potential disease-modifying...

2025 Total Revenue and Adjusted EBITDA1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026  Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA1 of $18 million and Adjusted EBITDA Margin1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year...

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer’s novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026 Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company’s balance sheet; ended 2025 with $505.4 million in cash, cash equivalents,...

– Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results – – Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 – – New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development – – Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 – – Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end – – Up to $250 million non-dilutive, multi-tranche debt financing secured from Pharmakon...

– Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) – – FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC – – Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 – – Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 – – Company to host conference call today at 8 a.m. ET / 5 a.m. PT – SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in...